Previous Study: TRIO041
Next Study: TRIO039

Studies & Results


A Phase I, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of DZD1516 in Combination with Trastuzumab and Capecitabine, or DZD1516 in Combination with T-DM1, in Patients with Metastatic HER2 Positive(HER2+) Breast Cancer

View FDA Study

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at